Kyverna Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
KYTX$4.88+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share data)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $31,806 | $124,093 |
| Available-for-sale marketable securities | 167,621 | 155,160 |
| Prepaid expenses and other current assets | 7,115 | 3,700 |
| Total current assets | 206,542 | 282,953 |
| Restricted cash | 551 | 551 |
| Property and equipment, net | 1,326 | 1,546 |
| Operating lease right-of-use assets | 7,848 | 3,568 |
| Finance lease right-of-use assets | 112 | 305 |
| Other non-current assets | 3,444 | 4,903 |
| Total assets | $219,823 | $293,826 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $2,933 | $5,306 |
| Accrued compensation | 5,481 | 9,990 |
| Accrued license expense – related party | 3,750 | 3,750 |
| Other accrued expenses and current liabilities | 9,112 | 13,472 |
| Operating lease liabilities, short-term portion | 1,400 | 3,662 |
| Finance lease liabilities | 126 | 307 |
| Total current liabilities | 22,802 | 36,487 |
| Operating lease liabilities, net of short-term portion | 6,589 | 320 |
| Term loan | 24,883 | 24,743 |
| Total liabilities | 54,274 | 61,550 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 490,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 61,570,247 and 60,389,893 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively. | 1 | 1 |
| Additional paid-in capital | 668,564 | 657,005 |
| Accumulated other comprehensive (loss) income | (142) | 97 |
| Accumulated deficit | (502,874) | (424,827) |
| Total stockholders’ equity | 165,549 | 232,276 |
| Total liabilities and stockholders’ equity | $219,823 | $293,826 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.